MedTrace Logo

Comparative Trial of Entecavir Versus Adefovir in the Treatment of Chronic Hepatitis B Infection

NCT00096785 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 69

Last updated 2010-08-10

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate antiviral activity and efficacy of entecavir (ETV) compared to adefovir in adults with chronic hepatitis B who have not been treated yet with an antiviral medicine.

Conditions

Interventions

DRUG

entecavir

Tablets, Oral, ETV 0.5 mg, once daily, up to 96 weeks

DRUG

adefovir

Tablets, Oral, ADV 10 mg, once daily, up to 96 weeks

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-12-31
Primary Completion
2006-01-31
Completion
2008-04-30

Countries

  • United States
  • Canada
  • Hong Kong
  • Indonesia
  • Philippines
  • Singapore
  • Taiwan
  • Thailand

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00096785 on ClinicalTrials.gov